A New Path Forward: The Therapeutic Potential of Next Generation BTK Inhibitors in CLL/SLL
Targeted agents such as Bruton tyrosine kinase (BTK) inhibitors dramatically changed the treatment landscape for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Unfortunately, challenges with tolerance and resistance are pervasive with these agents. Novel highly selective, non-covalent (reversible) BTK inhibitors that may overcome these challenges are undergoing investigation in clinical trials and have the potential to significantly enhance the treatment of CLL/SLL. In early clinical trials, these agents improved overall response rates, irrespective of prior therapy or mutation status.
A New Path Forward: The Therapeutic Potential of Next Generation BTK Inhibitors in CLL/SLL
Point-of-Care Learning
Targeted agents such as Bruton tyrosine kinase (BTK) inhibitors dramatically changed the treatment landscape for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Unfortunately, challenges with tolerance and resistance are pervasive with these agents. Novel highly selective, non-covalent (reversible) BTK inhibitors that may overcome these challenges are undergoing investigation in clinical trials and have the potential to significantly enhance the treatment of CLL/SLL. In early clinical trials, these agents improved overall response rates, irrespective of prior therapy or mutation status.
Expiration Date: February 24, 2023
CME/CE is no longer available for this activity
